Publicacións nas que colabora con María José Brión Martínez (111)

2025

  1. Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score

    European heart journal, Vol. 46, Núm. 3, pp. 273-284

  2. Carvedilol versus flecainide treatment in idiopathic ventricular extrasystoles and tachycardias (CARFLECT IV) trial: Rationale and design

    Revista Portuguesa de Cardiologia, Vol. 44, Núm. 12, pp. 709-715

  3. Challenges of genetics in the diagnosis of sudden cardiac death. Interest for forensic and legal medicine

    Medicina Clinica, Vol. 164, Núm. 3, pp. e1-e7

  4. Epigenetic regulation of electromechanical continuity might determine phenotypic heterogeneity in SCN5A mutation carriers in Brugada syndrome

    Scientific Reports, Vol. 15, Núm. 1

  5. Prevalence and relevance of H558R in the efficacy and toxicity of flecainide in patients with atrial fibrillation: a cohort study

    Heart, Vol. 111, Núm. 4, pp. 159-165

  6. Relevance of CYP2D6 in the Efficacy and Toxicity of Flecainide in Patients With Atrial Fibrillation:. Cohort Study

    Journal of Cardiovascular Pharmacology, Vol. 86, Núm. 4, pp. 384-390

2024

  1. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Detection of the Copy Number Variants of Genes in Patients with Familial Cardiac Diseases by Massively Parallel Sequencing

    Molecular Diagnosis and Therapy, Vol. 27, Núm. 1, pp. 105-113

2022

  1. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Association of variants in MYH7, MYBPC3 and TNNT2 with sudden cardiac death-related risk factors in Brazilian patients with hypertrophic cardiomyopathy

    Forensic Science International: Genetics, Vol. 52

2020

  1. Genetic variants of uncertain significance: How to match scientific rigour and standard of proof in sudden cardiac death?

    Legal Medicine, Vol. 45

  2. Polygenic risk score as a key factor in cardiovascular clinical prediction models

    Revista Espanola de Cardiologia, Vol. 73, Núm. 8, pp. 608-610

2019

  1. A Novel Calsequestrin 2 Deletion Causing Catecholaminergic Polymorphic Ventricular Tachycardia and Sudden Cardiac Death

    Revista Espanola de Cardiologia, Vol. 72, Núm. 8, pp. 681-683

  2. Genetic susceptibility in pharmacodynamic and pharmacokinetic pathways underlying drug-induced arrhythmia and sudden unexplained deaths

    Forensic Science International: Genetics, Vol. 42, pp. 203-212

  3. Sudden infant death as the most severe phenotype caused by genetic modulation in a family with atrial fibrillation

    Forensic Science International: Genetics, Vol. 43

2018

  1. Innovative Strategies in Heart Failure: Present and Future

    Archives of Medical Research, Vol. 49, Núm. 8, pp. 558-567

2017

  1. ABCC3 Polymorphisms and mRNA Expression Influence the Concentration of a Carboxylic Acid Metabolite in Patients on Clopidogrel and Aspirin Therapy

    Basic and Clinical Pharmacology and Toxicology, Vol. 120, Núm. 5, pp. 466-474

  2. Medico-legal perspectives on sudden cardiac death in young athletes

    International Journal of Legal Medicine, Vol. 131, Núm. 2, pp. 393-409

  3. Postmortem genetic testing should be recommended in sudden cardiac death cases due to thoracic aortic dissection

    International Journal of Legal Medicine, Vol. 131, Núm. 5, pp. 1211-1219